BioDelivery Sciences (BDSI) shares are plummeting today for almost 60% after the company announced the primary endpoint in its Phase 3 clinical study of a pain drug was not reached: BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain To summarize: BioDelivery Sciences BEMA Buprenorphine study for the treatment […]